Salvador
Martín Algarra
Consultor Médico
José Luis
Pérez Gracia
Consultor Médico
Publicaciones en las que colabora con José Luis Pérez Gracia (19)
2020
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
2018
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319
2017
-
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995
2016
-
Circulating melanoma exosomes as diagnostic and prognosis biomarkers
Clinica Chimica Acta, Vol. 454, pp. 28-32
2015
-
Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice
Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478
-
Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors
Clinical Chemistry, Vol. 61, Núm. 1, pp. 297-304
-
Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient
International Journal of Surgical Pathology, Vol. 23, Núm. 2, pp. 111-115
2014
-
Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy
PLoS ONE, Vol. 9, Núm. 2
-
Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients
Clinica Chimica Acta, Vol. 429, pp. 168-174
-
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707
2012
-
Immunostimulatory monoclonal antibodies for melanoma treatment
Emerging Therapeutics for Melanoma (Future Medicine Ltd.), pp. 81-91
2011
-
Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes
Oncologist, Vol. 16, Núm. 6, pp. 877-885
-
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142
-
Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386
2007
-
Carcinoma microcítico de pulmón
Revista de medicina, Vol. 51, Núm. 2, pp. 7-13
-
Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy
Oncologist, Vol. 12, Núm. 9, pp. 1151-1155
-
Small-cell lung cancer
Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 2, pp. 7-13
2005
-
Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature
Clinical Lung Cancer, Vol. 7, Núm. 2, pp. 138-140
-
Assessment of the value of confirming responses in clinical trials in oncology
European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532